U.S. Online Retail and Ecommerce Stock News

NasdaqGS:POWL
NasdaqGS:POWLElectrical

Is It Too Late To Consider Powell Industries (POWL) After Its Surging Share Price?

If you are wondering whether Powell Industries at around US$320 per share still offers value, it helps to separate headline returns from what the underlying valuation is actually saying. The stock has posted very strong returns, with gains of 26.4% over the last week, 71.5% over the past month, 172.6% year to date and 451.6% over the last year, plus a multi year return of more than 17x. Recent coverage has focused on Powell Industries as part of broader discussions around power...
NasdaqGS:FBNC
NasdaqGS:FBNCBanks

Evaluating First Bancorp (FBNC) After Earnings Beat Fuels Investor Optimism

First Bancorp (FBNC) is back on investors’ radar after its latest quarterly report, where revenue and net interest income exceeded analyst expectations and recent board appointments added fresh perspectives to the regional bank’s story. See our latest analysis for First Bancorp. The stock has been firming up, with a 1-day share price return of 2.11% and a year to date share price return of 16.07%. The 1-year total shareholder return of 45.49% and 3-year total shareholder return of 130.20%...
NasdaqGS:VECO
NasdaqGS:VECOSemiconductor

Veeco Instruments (VECO) Margin Compression And Q1 Loss Test Bullish Growth Narratives

Veeco Instruments (VECO) opened 2026 with Q1 revenue of US$158.3 million, basic EPS of roughly a US$0.01 loss, and trailing 12‑month EPS of US$0.39 on US$655.3 million of revenue, setting up a quarter where profitability was in focus. The company has seen quarterly revenue move from US$167.3 million and basic EPS of US$0.21 in Q1 2025 to US$158.3 million and a small loss in Q1 2026, while trailing 12‑month EPS moved from US$1.31 on US$717.3 million of revenue at Q4 2024 to US$0.39 on US$655.3...
NYSE:AIR
NYSE:AIRAerospace & Defense

Has AAR (AIR) Risen Too Far After Recent Aerospace And Defense Sector Interest

If you are wondering whether AAR at US$118.71 is still reasonably priced after a strong run, this article walks through what the current share price might imply about value. The stock has recent returns of 12.3% over 7 days, 4.1% over 30 days, 40.6% year to date and 101.0% over the last year, which naturally raises questions about how much upside or risk is now priced in. Recent headlines have focused on AAR's role within the broader Aerospace & Defense sector and how investors are reacting...
NasdaqGM:ADMA
NasdaqGM:ADMABiotechs

ASCENIV Pediatric Approval Tests ADMA Biologics Growth Story And Risks

FDA approves an expanded label for ASCENIV to include pediatric immunodeficiency patients aged two and older. The decision allows earlier intervention for immune compromised children and broadens ASCENIV’s eligible patient pool. The approval fulfills a key post marketing commitment for ADMA Biologics and may influence future commercial uptake. For ADMA Biologics (NasdaqGM:ADMA), this regulatory milestone arrives with the stock trading at $10.08 after a very large 5 year return and a 182.4%...
NasdaqCM:AHG
NasdaqCM:AHGHealthcare

Is Akso Health Group's (AHG) Early BCI Bet Quietly Redefining Its Long-Term Innovation Narrative?

In April 2026, Akso Health Group announced it had begun a next-generation Brain-Computer Interface research and development program, building foundational infrastructure to pursue ultra-high-resolution neural sensing, real-time AI neural decoding, and advanced interface design, with related patent applications pending. The company emphasized that it has not yet started human clinical trials, made any regulatory submissions, or generated revenue from BCI activities, underscoring the...
NYSE:ONTO
NYSE:ONTOSemiconductor

Onto Innovation (ONTO) Margin Reset From 21.3% To 10.3% Tests Bullish Growth Narratives

Onto Innovation (ONTO) has opened 2026 with Q1 revenue of US$291.9 million and basic EPS of US$0.68, setting a clear benchmark for how the rest of the year may shape up. The company has seen quarterly revenue move between US$218.2 million and US$291.9 million over the last six reported periods, while basic EPS has ranged from US$0.21 to US$1.30. This gives investors a concrete sense of how top line and per share earnings have tracked through recent cycles. With trailing 12 month net profit...
NYSE:PRGO
NYSE:PRGOPharmaceuticals

Perrigo (PRGO) Q1 Loss Of US$389.9 Million Tests Profit-Recovery Narratives

Perrigo (PRGO) opened Q1 2026 with revenue of US$969.2 million and a basic EPS loss of US$2.81, while net income excluding extra items came in at a loss of US$389.9 million. Over the past six reported quarters, revenue has ranged between US$969.2 million and US$1.14 billion and basic EPS has moved from a small profit of US$0.09 in Q3 2025 to a loss of US$10.20 in Q4 2025 and US$2.81 in the latest quarter, giving investors a wide view of how the income statement has changed across different...